Dynavax, AstraZeneca to research use of TLR-9 agonists for asthma

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Dynavax Technologies Corp. has entered into a research collaboration and license agreement with AstraZeneca plc for the discovery and development of Dynavax's TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease, according to a company news release.

AstraZeneca will be responsible for the development and worldwide commercialization of products arising out of the research program. Dynavax may have the opportunity to co-promote the products in the United States.

Dynavax will receive an upfront fee of $10 million plus research funding and preclinical milestones that could bring the total committed funding to $27 million, resulting in a total potential deal value of roughly $136 million.

Upon commercialization, Dynavax, a Berkeley, Calif.-based pharmaceutical company, will be eligible to receive royalties based on product sales.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.